👉 The start of a new year creates a natural moment for reflection and recalibration. Budgets are reviewed. Scientific priorities are discussed. Fundraising timelines are adjusted. Yet one decision often remains unchanged from the previous year. 👉 Patent strategy is treated as something already decided rather than something that deserves fresh leadership attention . For smart biotech CEOs, this is a missed opportunity. A company does not enter January in the same position it

👉 Every biotech founder knows the burn rate clock is ticking. You’ve mapped your milestones. You’ve got 12, maybe 18 months of runway. You’re pushing the science forward. But at some point, usually right after a delayed assay or a no from a lead investor, something shifts. 👉 Suddenly, the calendar starts driving your decisions more than the science does. You catch yourself wondering if the data is “good enough” to show. You rush internal meetings to hit external expectation

Investors in 2025 aren’t just backing biotech science—they’re judging execution. CEOs who can’t show scaling signals—operational rhythm, cross-team clarity, and a real scalability narrative—risk burning credibility, not just capital. This memo breaks down the three signals biotech leaders must master to win trust and funding.